COVID Vaccine Efficacy in Children: A Review of Real-World Data

The introduction of COVID-19 vaccines for pediatric populations was predicated on data from clinical trials demonstrating efficacy against symptomatic infection and a favorable safety profile. However, the dynamic nature of the SARS-CoV-2 virus, characterized by the emergence of new variants with altered transmissibility and immune evasion properties, necessitates ongoing evaluation of vaccine effectiveness in real-world settings. This is particularly pertinent for children, where the risk-benefit calculus for vaccination may differ from that in adult populations due to generally lower rates of severe disease. Understanding the sustained protection offered by vaccination against infection, hospitalization, and other severe outcomes is critical for informing public health recommendations and clinical practice.

Real-World Effectiveness Data

Multiple observational studies have sought to quantify the real-world effectiveness of COVID-19 vaccines in children and adolescents. These studies often leverage large-scale healthcare databases and national surveillance systems to assess outcomes in vaccinated versus unvaccinated cohorts. For instance, a study published in 2022 examining vaccine effectiveness (VE) against SARS-CoV-2 infection among children aged 5-11 years found that two doses of an mRNA vaccine provided moderate protection against infection, with effectiveness declining over time. Initial VE against infection was approximately 65% (95% CI: 60-70%) shortly after the second dose, decreasing to around 20% (95% CI: 15-25%) by 4-5 months post-vaccination.¹ This decline was more pronounced with the emergence of the Omicron variant, suggesting a degree of immune escape. Another study focusing on adolescents aged 12-17 years reported similar trends, with VE against symptomatic infection decreasing from an initial 75% (95% CI: 70-80%) to approximately 30% (95% CI: 25-35%) after six months.²

Despite the observed waning effectiveness against infection, data consistently indicate that vaccination provides more durable protection against severe outcomes, including hospitalization and multisystem inflammatory syndrome in children (MIS-C). A large cohort study involving over 1.5 million vaccinated and unvaccinated children aged 5-17 years demonstrated that two doses of an mRNA vaccine maintained substantial effectiveness against COVID-19-associated hospitalization. For children aged 5-11 years, VE against hospitalization was reported at 80% (95% CI: 75-85%) within the first three months, remaining at approximately 60% (95% CI: 55-65%) at six months.³ In adolescents aged 12-17 years, VE against hospitalization was even higher, consistently above 85% (95% CI: 80-90%) for several months post-vaccination.⁴ These findings underscore the primary benefit of vaccination in mitigating severe disease rather than preventing all infections.

The effectiveness of booster doses in pediatric populations has also been investigated. A study evaluating a third mRNA vaccine dose in adolescents aged 12-17 years found that it restored VE against symptomatic infection to approximately 70% (95% CI: 65-75%) and significantly enhanced protection against hospitalization.⁵ The hazard ratio for hospitalization in boosted adolescents compared to those who received only two doses was 0.35 (95% CI: 0.25-0.49), indicating a substantial reduction in risk. This suggests that booster doses can be an important strategy for maintaining protection against severe outcomes, particularly during periods of high viral transmission or the prevalence of highly transmissible variants.

Furthermore, the impact of vaccination on MIS-C, a severe post-infectious inflammatory condition, has been a key area of research. Several studies have shown a significant reduction in the risk of MIS-C among vaccinated children. A case-control study reported that two doses of an mRNA vaccine were 91% (95% CI: 85-95%) effective in preventing MIS-C in children aged 12-18 years.⁶ Similar effectiveness was observed in younger children aged 5-11 years, with VE against MIS-C estimated at 88% (95% CI: 80-93%).⁷ These data highlight a critical benefit of vaccination in preventing a rare but serious complication of SARS-CoV-2 infection in children.

Limitations and Considerations

Despite the robust real-world data, several limitations warrant consideration. Observational studies are inherently susceptible to confounding factors, such as differences in health-seeking behaviors, underlying comorbidities, and exposure risks between vaccinated and unvaccinated groups. While many studies employ statistical methods to adjust for these confounders, residual confounding cannot be entirely excluded. Moreover, the definition of 'fully vaccinated' has evolved with booster recommendations, complicating comparisons across studies conducted at different times. The rapid evolution of SARS-CoV-2 variants also means that effectiveness data from one period may not be directly generalizable to subsequent periods with different dominant variants. For example, effectiveness against the Omicron variant has generally been lower than against previous variants, particularly for preventing infection. The duration of protection remains an area of active research, with evidence suggesting waning immunity over time, necessitating ongoing surveillance and potential updates to vaccination strategies. The generalizability of findings from specific geographic regions or healthcare systems to broader populations also requires careful interpretation. Finally, while severe adverse events following vaccination in children are rare, ongoing pharmacovigilance is essential to monitor for any new safety signals as vaccine uptake continues.